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Abstract
Background: A method is outlined for the use of an individual-based stochastic model of parasite transmission
dynamics to assess different designs for a cluster randomized trial in which mass drug administration (MDA) is
employed in attempts to eliminate the transmission of soil-transmitted helminths (STH) in defined geographic
locations. The hypothesis to be tested is: Can MDA alone interrupt the transmission of STH species in defined
settings? Clustering is at a village level and the choice of clusters of villages is stratified by transmission intensity
(low, medium and high) and parasite species mix (either Ascaris, Trichuris or hookworm dominant).
Results: The methodological approach first uses an age-structured deterministic model to predict the MDA
coverage required for treating pre-school aged children (Pre-SAC), school aged children (SAC) and adults (Adults) to
eliminate transmission (crossing the breakpoint in transmission created by sexual mating in dioecious helminths)
with 3 rounds of annual MDA. Stochastic individual-based models are then used to calculate the positive and
negative predictive values (PPV and NPV, respectively, for observing elimination or the bounce back of infection) for
a defined prevalence of infection 2 years post the cessation of MDA. For the arm only involving the treatment of
Pre-SAC and SAC, the failure rate is predicted to be very high (particularly for hookworm-infected villages) unless
transmission intensity is very low (R0, or the effective reproductive number R, just above unity in value).
Conclusions: The calculations are designed to consider various trial arms and stratifications; namely, community-
based treatment and Pre-SAC and SAC only treatment (the two arms of the trial), different STH transmission
settings of low, medium and high, and different STH species mixes. Results are considered in the light of the
complications introduced by the choice of statistic to define success or failure, varying adherence to treatment,
migration and parameter uncertainty.
Keywords: Soil-transmitted helminths, Interrupting transmission, Cluster randomized trial design, Stochastic models
of transmission, Mass drug administration impact
Background
The past decade has seen much expansion in mass drug
administration (MDA) programmes to control helminth
infections in regions with endemic infection. The major
helminths, in terms of the global burden of disease, are
Wucheria bancrofti (lymphatic filariasis - LF), Onchocerca
volvulus (Onchocerciasis), Schistosoma spp. (schistosomia-
sis - SCH) and the soil-transmitted helminths (STH -
Ascaris lumbricoides, Trichuris trichuria and the hook-
worms, Necator americanus and Ancylostoma americanus).
For LF and onchocerciasis, MDA is community based,
covering all age groups. Progress in many countries with
endemic LF and onchocerciasis infection has been very
good, with high coverage achieved and concomitantly,
prevalence has fallen to very low levels. For the schisto-
somes and STH, MDA is typically targeted at pre-school
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aged children (Pre-SAC) and school aged children (SAC),
although in areas with LF control programmes the use of
community wide MDA with albendazole as part of dual
therapy for LF also acts to control STH. The objective of
the World Health Organisation (WHO) for STH is morbid-
ity control in those age groups viewed as most at risk.
Coverage of STH treatment has risen slowly over the
past decade with figures running just above 63.3% for
SAC of those judged to need treatment and around
48.2% for Pre-SAC coverage in 2015 [1]. The target for
2020 is 75% for both Pre-SAC and SAC and it is hoped
that the steady increase can be maintained to meet this
target [2, 3]. The picture for the schistosomes is less
encouraging, SAC and Adult coverage being around 42.2
and 11.7%, respectively.
In recent years, discussion has turned to the question of
whether the emphasis of the WHO strategy for both STH
and SCH should shift from morbidity control to the inter-
ruption of transmission [4, 5]. One reason for this‚ is a
growing body of analysis that suggests that targeting
Pre-SAC and SAC alone is unlikely to stop the transmis-
sion of STH in most settings, due to a large reservoir of
infection in the adult age classes. This is especially true for
hookworm, where the majority of worms are typically har-
boured by adults [6, 7]. In very low transmission settings
just treating children could in principle interrupt trans-
mission, but this is only true for very low values of the
basic reproductive number, R0, which is an overall
measure of transmission success in a defined location in
the absence of any density-dependent constraints [8].
Throughout this paper, we use the magnitude of R0 to
characterise the intensity of transmission in a defined
setting, as is conventional in much of infectious disease
epidemiology but less so at present in helminthology. For
dioecious macroparasites, R0 defines the average number
of offspring produced by a female worm that survive to
reach reproductive maturity in the human host. If this
number is less than unity in value in a defined location,
the parasite cannot persist. The aim of control is therefore
to reduce R0 < 1. In the presence of density-dependent
processes, such as a reduction in mating success in dioe-
cious species when worm burdens are low, transmission
can fall below the level required to maintain the parasite
within the human host population even when the value of
R0 is a little above unity in value [8].
An obvious corollary of the maintenance of a reservoir
of infection in adults, is that MDA must continue for-
ever in the absence of improvements in the prevailing
sanitation and water supply provisions in resource poor
settings where STH infections are endemic. Improve-
ments in sanitation and hygiene, that act to reduce egg
or larval contamination of human habitats, act to reduce
the value of the intrinsic value of R0, provided they are
sustained indefinitely.
If emphasis shifts to transmission interruption, the ques-
tion emerges as to whether or not transmission can be
interrupted by MDA alone, acknowledging the practical dif-
ficulties of improving sanitation and hygiene to a level that
can provide benefit in many settings. A series of recent ana-
lyses, based on deterministic and stochastic models of hel-
minth transmission and MDA, suggest that interruption of
transmission may be possible using MDA alone, even in
high transmission settings, provided drug coverage is high
and all age groups in the community are targeted [3, 6, 9].
The use of mathematical models in neglected tropical
disease (NTD) research is relatively recent, in contrast to
other areas of infectious disease epidemiology. As such,
model predictions are not yet an integral part of policy
formulation. This is despite the fact that the theory under-
pinning recently published mathematical models of the
transmission dynamics of helminths and the impact of
MDA dates back to the mid-1980s [10–12]. In addition,
the dynamics of helminths are in general much more
predictable than many of the directly transmitted viral and
bacterial infections due to the apparent absence of signifi-
cant acquired immunity such that post-treatment infec-
tion levels bounce back to pre-control levels in a
monotonic manner. This stability is in part due to the
relatively long life expectancy of the adult worms in the
human host (1 to 10+ years depending on the species of
helminth).
Evidence to support changes in WHO policy for con-
trol or elimination of STH by MDA should be based on
the highest quality evidence available, ideally from ran-
domized trials designed to test the hypothesis derived
from theory that MDA alone can interrupt the local
transmission of STH. Under a programme funded by the
Bill and Melinda Gates Foundation, entitled DeWorm3,
such trials are being planned to start in mid 2017. At the
centre of the design of these trials is the question ‘How
do you measure transmission interruption?’ This ques-
tion is the topic of this paper. It is addressed at two
levels. First, we examine what is meant by the phrase
‘transmission interruption’ for a dioecious helminth with
long-lived life-cycle stages. We then turn to the practical
issue of how do you determine if you have been success-
ful, given the stochastic nature of the real world?
Heterogeneities in trial settings intrude very directly on
trial design, sample size choice and the likely probability
distributions of different outcomes. To address this un-
certainty, stochastic models are employed which give a
likelihood of any given outcome by defining a probability
of observing the outcome.
Methods
Interruption or elimination of parasite transmission
The word ‘control’ has many connotations in the field of
public health. For infectious diseases‚ WHO uses the
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1998 definitions proposed by Dowdle [13]. He defined
control as a reduction in the incidence, prevalence, mor-
bidity or mortality of an infectious disease to a locally
acceptable level; elimination as reduction to zero of the
incidence of disease or infection in a defined geograph-
ical area; and eradication as permanent reduction to zero
of the worldwide incidence of infection [13].
His definitions were largely framed for microparasitic
infections, where prevalence is the major epidemio-
logical measure and incidence is defined as new infec-
tions (change from susceptible to infected) per unit of
time. For the macroparasitic helminths, where parasite
burden determines morbidity, incidence can be defined
either as the acquisition of new individual parasites
which may or may not influence prevalence depending
on the worm load in the exposed host, or by the conver-
sion of an uninfected person to an infected individual.
The definitions of Dowdle still hold with some minor
modification.
The elimination of transmission is the reduction of the
establishment of new adult parasite infections in the hu-
man host to zero in a defined locality. This state will arise
over many years, in which the rate of establishment slowly
decays to zero after many rounds of mass drug adminis-
tration. However, some important biological concepts
underpin this state. The first is central to the study of the
epidemiology and control of infectious diseases and con-
cerns the basic reproductive number, R0, which must ex-
ceed unity in value for parasite persistence [12].
However, for dioecious species, such as all of the
nematode parasites of humans, this concept is modified
by the need for a female worm to find a male mate in
the host, given that the adult worm cannot leave the
host to complete this task. In other words, in the case of
STH species, both male and female worms must be in
the same host to produce fertile offspring which exit the
host as eggs or larvae and perpetuate the life-cycle. As
such a critical mean adult parasite density exists in the
host population to sustain effective sexual reproduction.
This was first noted by Macdonald [14] for schistosome
species, and elaborated on by May [15], to include the
assumption that worms are aggregated in their distribu-
tion in human communities. Macdonald had assumed
the distribution was Poisson but many observational epi-
demiological studies subsequently demonstrated that the
distributions are highly aggregated and negative bino-
mial in form with aggregation parameter k which varies
inversely with the degree of worm clumping [10, 12].
The studies of Macdonald [14] and May [5] led to the
concept of a transmission breakpoint in the mean worm
load, below which the attractor of the dynamical system
is parasite extinction. The theory behind this concept is
laid out in Anderson & May [12], and is based on a sys-
tem of differential or partial differential equations
describing the population dynamics of the adult parasite
that have three equilibrium points for the mean worm
burden per host in a defined human community;
namely, two stable points which are endemic parasite in-
fection and parasite extinction, separated by an unstable
point which is the ‘transmission breakpoint’. The magni-
tude of this breakpoint is strongly influenced by the de-
gree of worm aggregation in the human host. High
aggregation increases the likelihood of the parasite find-
ing a mate and therefore lowers the value of the break-
point mean worm load. A further biological factor
influences the value of the breakpoint, namely, the sex-
ual habits of the parasite. Parasites may be monogamous
or polygamous, although little is understood about these
proclivities for the helminth parasites of humans. It is
widely assumed that STH species are polygamous and
schistosomes are monogamous, although the hard evi-
dence for this is very limited at present. The transmis-
sion breakpoint is lower when parasites are polygamous,
since a single male can successfully mate many females
in highly aggregated populations when males are scarce.
It is important to note that the breakpoint may be
crossed even when R0 is slightly greater than unity in
value, since the definition of this parameter is based on
population growth in the absence of density-dependent
constraints. Mating success is a density-dependent
process, since its magnitude decreases as worm burdens
fall [8].
The net outcomes of the existence of a transmission
breakpoint or threshold are threefold. First, and most
importantly, if this breakpoint is crossed say by the ac-
tion of MDA, the extinction state is an attractor which,
once achieved, is stable in the absence of parasite (and
hence host) immigration. Second, its existence implies
that the critical point for parasite extinction (and hence
the interruption of transmission) is not R0 < 1, but a
value of R0 which results in the mean worm load falling
below the breakpoint. This may be a value significantly
above unity, such as a value of 2 to 3, depending on the
probability distribution of parasite numbers per host and
sexual habits (monogamous or polygamous). The third
is less obvious. Once the breakpoint threshold is crossed
(defined by either a mean worm burden perhaps mea-
sured indirectly by egg output in faeces, or by the preva-
lence of infection) by a defined MDA coverage - the
attractor is parasite extinction. Even if MDA stops with
infection still present, the parasite population will move
to extinction (without any immigration of new infec-
tions), but as noted above, it will take time to achieve
‘no new infections’. The epidemiological measurement
of the breakpoint is based on the probability distribution
of parasite numbers per host and either of the two sum-
mary statistics of this distribution can be employed;
namely, the mean, or the proportion infected which
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defines the prevalence of infection. Note, however, the
relationship between these two summary statistics is
critically dependent on the degree of worm aggregation.
For example, in the case of a negative binomial distribu-
tion, which is commonly observed for STH (based on
worm expulsion or egg output), the relationship where
M is the mean, P is the proportion infected and k is the
aggregation parameter, is given by
P ¼ 1− 1þM=kð Þ−k ð1Þ
In practice, within STH parasite control programmes,
many complications surround these concepts including
the definition of the spatial region within which elimin-
ation is targeted (spatial scale), the sensitivity of diagnos-
tic tools to determine the prevalence and intensity of
infection, immigration and emigration of people to and
from the defined area, the demography of the host popu-
lation, and control programme impact on the degree of
parasite aggregation in the communities targeted (chan-
ging values of k in Eq(1)).
Before turning to the description of an approach to
randomized trial design to test the concept of transmis-
sion elimination, some issues surrounding what must be
measured are briefly addressed.
Migration and demography
In regions where STH are endemic, poverty and con-
comitantly poor employment opportunities are wide-
spread. As a direct consequence, migration in and out of
communities, typically by young adult males, to find
employment is common. Figure 1 shows an illustrative
example for the age and gender structured demography
of a community in India in 2015 (data from the US Bureau of
Population and Census; http://www.census.gov/population/
international) and a hypothetical distribution of those in the
community who are sampled for STH infection by their
presence or eligibility. For males, many adults are ab-
sent, while for females those in the ‘pregnancy’ age
classes are not eligible for treatment with albendazole
or mebendazole due to specifications in the WHO
guidelines for the treatment of pregnant women. This il-
lustrative example shows clearly that treatment coverage
calculations designed to move the mean worm burden
below the transmission breakpoint must take account of
the ‘true’ demography and the ‘sampled/treated’ popula-
tion. Second, it also illustrates the potential dangers of
migrant labour returning to the communities and reintro-
ducing infection if they have not been treated when absent
or not immediately on their return. Trials should be
designed to take account of these factors.
The importance of measuring adherence to treatment
A recent review by Shuford and colleagues [16]‚ of ad-
herence to drug treatment in MDA control programmes
for helminth infections, revealed that very few studies
had recorded both coverage as a fraction of the target
populations, and the influence of age and gender on
adherence. Accurate data on adherence, with appropriate
stratifications, are essential as is a longitudinal compo-
nent to adherence estimates for individuals. For ex-
ample, published studies to date do not record the
behaviour of individuals over multiple rounds of treat-
ment. Clearly, if there are persistent non-adherers to
treatment they will act as a reservoir of infection even if
overall coverage is high. In trial designs to test transmis-
sion interruption, longitudinal adherence of individuals
should be carefully recorded, and where possible directly
observed methodologies should be employed.
Diagnostics
New diagnostic tools have recently been developed for
STH infections to replace the gold standard eggs per
gram of faeces measures such as Kato Katz. One
Fig. 1 True demography and sampled demography. Demography of India 2015 (source http://www.census.gov/population/international/data/
idb/informationGateway.php) (blue bars are the full population; orange bars are the sampled population)
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example is qPCR (quantitative polymerase chain reac-
tion) which has been tested as a quantitative tool for
both egg output in stools and worm burdens by Easton
and colleagues [17]. Such studies reveal that at low in-
fection intensity levels, qPCR is much more sensitive in
detecting the presence of eggs in stools reflecting low
worm burdens. Clearly, in elimination of transmission
studies, highly sensitive quantitative tests are ideally re-
quired that are well calibrated against existing diagnostic
tools such as Kato Katz. An example is presented in
Fig. 2 from the work of Easton and colleagues [16]. It re-
cords a reasonably tight linear relationship (on a log-log
scale, with values define as log(KK + 1)) between the
concentration of egg antigen DNA in faecal samples
(ng/μl) and measures of eggs per gram of faeces by Kato
Katz (KK). Note how many qPCR tests are positive for
zero Kato Katz results. In randomized trials, especially
as the transmission threshold is approached after mul-
tiple rounds of MDA at high treatment coverage, qPCR
tests are clearly to be preferred. In country-wide MDA
programmes, the costs of such tests and the associated
equipment plus labour implications are yet to be evalu-
ated [17–19].
Species composition and drug efficacy
The three most prevalent STH are Ascaris lumbricoides,
Trichuris trichuria, and hookworms both Necator ameri-
canus and Ancylostoma duodenale. The widely used
drugs for the treatment of these infections, albendazole,
mebendazole and pyrantel pamoate, have differing effica-
cies against the same species and different species, as
reviewed by Vercruysse et al. [20], Levecke et al. [22]
and Keiser & Utzinger [21]. For example, with albenda-
zole, reported average efficacies against Ascaris, Tri-
churis and hookworm are 99, 50 and 95%, respectively.
In the case of Trichuris dual therapy is required using
albendazole and ivermectin to gain acceptable levels of
efficacy [23]. The effective rate of treatment in MDA
programmes is coverage times drug efficacy, and thus
both variables should be taken into account in the de-
sign of trials.
Stochastic effects
The real world is replete with heterogeneities, which
may or may not be measurable in given transmission
and control settings. Chance effects are very important.
The use of the word chance is an economy of thought,
in the sense it captures what is poorly understood or
cannot be measured. In such settings, stochastic models
based on the known processes that determine the trans-
mission dynamics of the parasites are required to assess
the probability distribution of possible outcomes such as
success in breaking transmission. Typically, the mean of
this stochastic distribution will be equivalent to the sin-
gle outcome predicted by a deterministic model. How-
ever, this is not always true if many nonlinearities are
present in the biological system under study, as may be
the case for the transmission dynamics of helminths
with sexual reproduction and density-dependence in key
processes such as egg production [12, 24, 25]. In ran-
domized trials of MDA impact on helminth transmis-
sion, stochastic effects will be very important and hence
must be accounted for in trial design. A further import-
ant advantage of individual-based stochastic models is
their ability to present individual patterns of adherence
to treatment, and predisposition to light or heavy infec-
tion, over time.
Simulation of randomized trials
Clinical trials are costly to perform to test a new drug
therapy, or a community-based approach to disease con-
trol using vaccines or drugs. Increasingly, the pharma-
ceutical industry is turning to simulation techniques to
assess the likely impact of a given trial design and
defined endpoints to help reduced costs and increase
precision before implementation [26]. Computer simula-
tion of randomized trials, sometimes based on well-
defined mathematical models of the key biological and
epidemiological processes, has evolved over the past two
Fig. 2 qPRC compared with Kato Katz. qPCR diagnostics test results for a Ascaris lumbricoides and b Necator americanus compared with eggs per
gram of faeces determined by Kato Katz (from [17])
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decades from a simple instructive game to detailed
simulation models yielding pharmacological and disease
outcome results [27].
Such an approach has rarely been used in community-
based randomized trials for NTDs and not at all for the
STHs. Given the challenge of accurately measuring
transmission interruption in heterogeneous settings,
simulation techniques are suggested in the following sec-
tion which describes a potential method for the design
of a randomized cluster-based trial for helminth trans-
mission interruption, using both community wide and
Pre-SAC- plus SAC-based MDA treatment programmes.
A methodological approach to trial design based on the
transmission dynamics of STH under repeated rounds of
MDA
Before starting to develop a trial design the outcome
(transmission elimination or failure to eliminate) that is
been tested needs clear definition, as does the statistic to
be used to measuring this outcome. This involves all
sorts of variables such as, for example, diagnosis specifi-
city and sensitivity of the infection/no-infection status of
a participant. We consider a series of issues on which
decisions are required in the following subsections.
The first task in trial design is to assess which
community-based approach is to be adopted in terms
of which age groups are to be targeted, what level of
drug coverage in each age group is required to break
transmission, how frequently should it be delivered,
what transmission settings should the trial be con-
ducted in (low, medium or high transmission settings
or all three), over what duration of time is the trial to
be conducted, and how long will post-trial monitoring
be continued to assess if transmission has ceased once
MDA is stopped. The simplest way to do this at the
start of design is to be guided by deterministic models,
to get some idea of what level of coverage is required,
and for how long, to cross the breakpoint, before mov-
ing to stochastic formulations to predict the likelihood
of the outcomes of elimination and bounce back at
various times post the cessation of MDA. It is also im-
portant to note that the linkage of the DeWorm3
(http://www.nhm.ac.uk/our-science/our-work/sustain-
ability/deworm3.html) programme of research on STH,
to current LF control programmes where community
based MDA has often significantly reduced the burden
of STH, implies that starting at low to medium levels of
STH infection (an effective reproductive number R <
R0) is the most likely situation in which the trials will
be conducted. In these circumstances, a back calcula-
tion of the original R0 will have to be made based on
knowledge (even if partial) of past MDA coverage. The
methods required to perform these calculations are
described in a companion paper [28].
As mentioned earlier, the purpose of the trial is to
ascertain if intensified treatment regimens across defined
age classes can interrupt transmission for STHs. Once
MDA stops, which age profiles of worm burdens in the
host population lead to elimination in the long term and
which to parasite bounce back are not known in ad-
vance. The main role of stochastic disease transmission
models is to try and resolve this issue and to determine
what time point post the cessation of treatment would
maximise the likelihood of detecting which outcome will
emerge in a given village, or village cluster. We need to
find a threshold reflecting the parasite burden or preva-
lence of infection in the population at the end of the
study that can discriminate between the two possible
long-term outcomes - elimination and bounce back. It
needs to be sensitive, specific and easily measurable in
the field. The models must also provide clear guidance
on when to measure this statistic post MDA cessation to
maximize the likelihood of detecting either interruption
or bounce back given the non-linear dynamics of the
system under MDA and when it ceases. The approach
adopted in World Health Organisation guidelines for the
filarial worms is to define a prevalence of infection
below which (< 1%) MDA can be stopped, since it is
assumed that this marks the cessation of transmission.
Our approach is different, since the judgement on
whether or not transmission has ceased is based on
mathematical models of transmission using parameter
estimates based on field epidemiological research, not
guesswork. In both approaches, however, the quality of
the diagnostic measure employed to determine preva-
lence is clearly very important.
A second important aspect of the trial is that the ability
of a given program of treatment to bring about elimin-
ation will depend strongly on a number of covariates,
some of which can or should be recorded at baseline. Key
among these factors are transmission intensity (as repre-
sented by prevalence and the mean eggs per gram of
faeces (epg) intensity of infection measure, stratified by
age group), who has been treated in the past stratified by
age group, drug coverage by age group of past treatment,
STH species mix and past history of LF treatment. A key
feature of the trial will be to investigate how these baseline
covariates affect the ability of a given treatment program
to bring about elimination. A further desirable property of
the elimination statistic discussed above is that its critical
value should be, as far as possible, independent of the
baseline covariates or, at least, depend on them in a simple
predictable way. For the transmission model, different
baseline states, such as low medium or high baseline prev-
alences of infection, can be reproduced through the choice
of model parameter values. Hence from the modelling
point of view, it is important that the elimination statistic
should be largely independent of the parameters that
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govern the covariates. A more detailed discussion of the
dependence of this statistic on various factors in the trial
design (number of units, e.g. villages) per cluster, number
of clusters and sample size (number of people sampled)
per cluster unit, are described in a companion paper [29].
Overall, the model simulations are designed to give
clear guidance on cluster randomized trial design once
parameter estimates are made from the baseline epi-
demiology. The key issues can be summarised as follows.
(i) What measure of infection to use - prevalence or
average intensity? (ii) Which age group or groups should
be monitored or should it be the whole population (this
depends on the dominant STH species)? (iii) What
period of time should elapse post MDA cessation to
judge outcome (bounce back or elimination)? (iv) What
should be the sample size of people examined in each
village and what age groups should they be drawn from?
(v) How many villages should be included in a cluster?
(vi) Should cluster be chosen on the basis of similarities
or proximity (i.e. similar baseline prevalences of infec-
tion or spatial colocation)? (vii) How many clusters
should be employed? (viii) What should the minimum
population size be in a village to be included in a
cluster?
Arms of the trial and stratifications
DeWorm3 has specified that the trial of breaking trans-
mission will be a cluster randomized design or some
variant of this [5]. The concept is simply a development
on the framework of the classic randomized controlled
trial in which groups of subjects (as opposed to individ-
ual subjects) are randomized. Cluster-randomized con-
trolled trials are also known as cluster-randomized trials,
group-randomized trials and place-randomized trials.
These groups of people may belong to a particular vil-
lage or community, be in a certain location, or belong to
some defined grouping such as an age class. Stratifica-
tions in each arm involve the covariates mentioned earl-
ier such as STH species mix, MDA coverage, past
history of community-based LF treatment (in other
words the baseline prevalence of STH infection), and the
prevailing transmission intensity.
What age groups, of the three major groupings Pre-
SAC (1–4 years of age), SAC (5–14 years of age) and
Adults (15+ years of age), should be targeted for treat-
ment? Given that current WHO policy is to treat only
Pre-SAC and SAC, yet analyses point clearly to the
merits of treating the whole community if practically
feasible [8], one possible approach is for one arm to fol-
low the current WHO policy, and the other arm struc-
tured to treat all age groups (bar those less than 1 year
old where treatment guidelines suggest no treatment at
present for safety reasons) to provide evidence either in
support of current policy or for a change in policy to
community wide treatment. The broad structure is
therefore for only two arms. This is the design laid out
for an ongoing study in Kenya [5].
It should be noted that in areas where hookworm is
the dominant infection, the arm treating only Pre-SAC
and SAC will fail to break transmission since most of
the worms are harboured by adults. As published ana-
lyses suggest, even for Ascaris (treating with albendazole
or mebendazle only) and Trichuris (treating with alben-
dazole and ivermectin), when transmission intensity is
very high (R0 values in excess of 3), only treating Pre-
SAC and SAC will struggle to break transmission unless
previous LF MDA has taken the value of the effective re-
productive number, R, to close to unity [4, 6, 8, 30–34].
Ideally, only medium and low transmission settings
(overall R0 in range 1–2.5, or effective R just above 1 in
areas that have experienced significant levels of treat-
ment perhaps due to an ongoing LF control programme
prior to the initiation of the trial) should be chosen if
the trials are to be completed within 5 years [9]. This
would add two stratifications on top of the two age
grouping arms to be targeted for treatment. Estimation
of R0 or the effective R is clearly essential before the trial
starts in each village community (a cluster) in order to
calculate what level of treatment is required to interrupt
transmission. This can be achieved from baseline cross
sectional age intensity and age prevalence epidemio-
logical data [28, 35] plus knowledge of past MDA cover-
age for LF control, ideally stratified by age group.
The next high-level stratification within an arm
concerns the STH species mix present in a trial site. If
Trichuris is the dominant infection, dual therapy may be
required. If not, single albendazole (preferable for hook-
worm) or mebendazole treatment will suffice. Different
calculations for the design of the trial will be required
depending on what species mix is present in a chosen
location.
The final stratification concerns the frequency of treat-
ment. More frequent treatment, such as every 6 months,
can speed the movement towards transmission interrup-
tion, especially in areas of high transmission for Ascaris
and Trichuris. Weighed against this, however, is the
logistical framework required to deliver very frequent
treatment at scale, and the disruption to the commu-
nities in which treatment is delivered. For these rea-
sons the calculations that follow are based on annual
treatment.
Deterministic calculations of breakpoint surfaces
Calculations of the breakpoints in transmission, in terms
of the mean worm burden or prevalence of infection
below which transmission is interrupted, have been pub-
lished over the past few years for each of the major STH
species and schistosome species [4, 6] using different
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levels of coverage for the three major age groupings Pre-
SAC, SAC and Adults [4, 6, 9, 33–35]. For ethical rea-
sons, all individuals who are diagnosed with infection at
any time point and in any arm of the trial must be
treated.
In all such calculations, the duration of time required
to cross the breakpoint is a key concern. Ideally within
a 5-year horizon, 3 years would be taken up with three
annual rounds of treatment and 2 years of follow up to
assess if transmission is eliminated. The models on
which these developments have taken place are those
described by Anderson [10], Anderson & May [11, 25]
and Anderson & Medley [31].
An illustration of the time predicted to be required
(given annual treatment) to cross the breakpoint, for
various levels of effective treatment coverage in Pre-
SAC, SAC and Adults, is presented in Table 1 for
hookworm and Ascaris, both in medium intensity
transmission settings. The vertical axis denotes cover-
age of Pre-SAC and SAC combined, while the horizon-
tal axis denotes coverage of adults. The figures within
the Table 1 are the number of years predicted to be
needed, at the defined coverage levels, to break trans-
mission; ‘na’ denotes that the defined levels of cover-
age will not break transmission. Note that for most
combinations, the number of years required is greater
than four. To achieve transmission elimination for As-
caris and hookworm in 3–4 years, and within a 5–6
year time horizon, allowing for two further years of
monitoring once MDA has stopped, requires coverage
levels in both age groupings of around 80–90% (the
highlighted numbers in the table). In many areas of
endemic STH, LF is also present and the communities
in these locations may have had a number of years of
community-based MDA treatment (all age groupings).
This makes life somewhat easier, as illustrated in
Table 2 for Ascaris with a pristine R0 of 2.21. If two to
5 years of high community-based MDA coverage (for
LF control) have taken place before the STH trial, then
lower levels of coverage are required to break trans-
mission in 2 to 3 years [28].
Note that for the trial arm in which only Pre-SAC and
SAC are treated, no level of coverage for either Ascaris
or hookworm is predicted to break transmission with
5 years unless past LF control over 5 years or so has re-
duced the value of R to just above unity.
Much parameter uncertainty surrounds key transmis-
sion processes of the major STH species. These include
parasite aggregation as defined by the negative binomial
parameter, k, the severity of density dependence in fe-
cundity, adult worm life expectancy and the cross-
transmission coefficients determining how infective
stages released by one age group infect other age groups
(33). Sensitivity analyses are required of defined ranges
of parameter uncertainty to see how this influences the
values in Tables 1 and 2. This is an essential step and it
can also be performed in the stochastic simulations de-
scribed later.
The steps in the suggested procedures, and the calcu-
lations required to arrive at these estimates of coverage,
are summarised in Fig. 3. Following these initial calcula-
tions, the next stage involves deciding on a statistic to
measure success or failure, and the simulation via an
individual-based stochastic model of the full probability
distribution of the time to breaking transmission, given
achievement of the required drug coverage of the age
groupings. This is addressed in the following section.
Statistic to measure success or failure, and which
epidemiological variable to assess
The two outcomes of interest in the trial are transmis-
sion interruption and failure to interrupt transmission.
In epidemiological terms this translates to elimination,
with the prevalence and mean intensity falling to zero
over a defined time period, and bounce back in both
statistics to the levels prevailing before the trial started
over a time scale largely influenced by the life expect-
ancy of the adult worm [25]. The positive predictive
Table 1 Number of annual rounds in years to transmission elimination predicted by the deterministic model with fitted parameters
to a medium transmission area for Ascaris (R0 = 2.34) and hookworm (R0 = 2.2). Albendazole drug efficacy is embedded in the
calculations. Numbers in bold reflect predictions, based on the deterministic model, of crossing the transmission threshold within
four years
Coverage of Pre-SAC & SAC (%) Coverage of adults (%) Coverage of adults (%)
0 20 40 60 80 100 0 20 40 60 80 100
0 na na na na na na na na 14 7 4 3
20 na na na na na na na na 11 6 4 2
40 na na na 20 15 13 na na 10 5 3 2
60 16 11 9 8 7 6 na na 9 5 3 2
80 7 6 5 5 4 4 na na 8 5 3 2
100 5 4 4 3 3 3 na na 8 4 3 2
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(PPV) or negative (NPV) predictive value [36] are appro-
priate measures. The PPV and NPV are the proportion
of positive and negative results in the trials (either mea-
sured by prevalence or mean intensity) that are true
positive and true negative results, respectively. The NPV
is defined as follows:
NPV = The number of true bounce backs detected/
(The number of bounce backs detected (true negatives)
+ The number of eliminations wrongly detected as
bounce backs (false negatives))
Conversely the PPV is defined as:
PPV = The number of true eliminations/(The number
true eliminations detected (true positives) + The number
of bounce backs wrongly detected as eliminations (false
positives))
A small PPV indicates that most of the villages which
are assessed to have eliminated transmission are false
positives and vice-versa. A small NPV indicates that
most of the villages that are assessed as having failed to
eliminate transmission have indeed successfully inter-
rupted transmission. In the event that past LF treatment
coverage has already broken STH transmission, post
cessation of the trial of STH treatment, the trajectories
of prevalence and intensity will continue to decay.
The choice of these two statistics is governed by the
fact that any trial to detect transmission elimination -
say based on the prevalence of infection eventually
falling to zero - will have to be run for some years post-
cessation of MDA since the time trajectory of prevalence
and intensity will be complex once the transmission
threshold is crossed and extinction becomes the at-
tractor in the non-linear dynamical system. This point is
clearly illustrated in Fig. 4, where two replicate stochas-
tic runs (see section below on stochastic models) of
three annual runs of chemotherapy to control Ascaris
infection resulting in either elimination or bounce back
are recorded by changes in the prevalence of infection
over time. Of all 300 replicates (representing different
villages with 500 people per village) 88% of the runs re-
sulted in elimination. However, note that when MDA
ceases for a village in which elimination eventually oc-
curs, the prevalence bounces upwards immediately after
cessation before moving to zero over the following
10 years. This long timescale for elimination once the
breakpoint is crossed is striking. However, note the
different trajectories of the elimination run versus the
bounce back run. In principle, it should be able to
discriminate between these different outcomes 2 years after
cessation of MDA. However, it is very clear that measuring
either prevalence or intensity at the point of treatment
cessation will fail to predict the eventual outcome.
Here the number in the definitions of PPV and NPV
refers to the number of villages (as the base unit in the
cluster randomized trial) in which either event occurs.
Table 2 Number of annual rounds in years to transmission elimination predicted by the deterministic model with fitted parameters
to a medium transmission area for Ascaris (R0 = 2.34) given 0, 2 or 5 years of community MDA for LF at an effective coverage level of
70% across each age grouping. Albendazole drug efficacy is embedded in the calculations. Numbers in bold reflect predictions,
based on the deterministic model, of crossing the transmission threshold within four years
Ascaris: equilibrium Ascaris: 2 years LF Ascaris: 5 years LF
Coverage of Pre-SAC & SAC (%) Coverage of adults (%) Coverage of adults (%) Coverage of adults (%)
0 20 40 60 80 100 0 20 40 60 80 100 0 20 40 60 80 100
0 na na na na na na na na na na na na na na na 5 3 3
20 na na na na na na na na na na na na 1 1 1 1 1 1
40 na na na 20 15 13 na na 23 13 10 9 1 1 1 1 1 1
60 16 11 9 8 7 6 9 7 6 5 4 4 1 1 1 1 1 1
80 7 6 5 5 4 4 4 4 3 3 3 3 1 1 1 1 1 1
100 5 4 4 3 3 3 3 2 2 2 2 2 1 1 1 1 1 1
Fig. 3 Flow chart summary of the steps in the suggested procedures and the epidemiological calculations required to arrive at the initial
estimates of MDA coverage in each age grouping prior to performing the stochastic simulations of the trial
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At low intensities of parasite transmission, detecting
small changes in exposure to infection via a sensitive
qPCR test is probably best based on the epidemiological
measure of prevalence. This is the statistic used in the
remainder of this paper. For a dioecious parasite, where
two worms of the opposite sex must be within the host
to produce viable offspring, the prevalence of infection
could be defined as 1 minus the proportion of people
with one or no worms. Given the uncertainties of past
history with parasites with average life spans of 1 year or
more, prevalence is defined as 1 minus the proportion of
people with no worms at a particular point in time.
Mean intensity could also be used to monitor the likeli-
hood of elimination or bounce back.
Individual-based stochastic model of transmission and
treatment
The first individual-based stochastic model of helminth
transmission was published by Anderson & Medley [31].
The paper examined how various heterogeneities, such as
predisposition to heavy or light infection, influenced the
probability distribution of parasite numbers per host. More
recently, Truscott and colleagues [35] have described an
individual-based stochastic transmission model for STH to
examine the impact of MDA. This structure is used in the
results presented in this paper and the reader is referred to
this publication for details of the event table and parameter
assignments for Ascaris, Trichuris and hookworm based on
published epidemiological studies that detail full cross-
sectional surveys of prevalence and intensity of infection.
The approach adopted in the analyses is to employ
the stochastic model to run replicate experiments in
a defined number of villages. The number of vil-
lages, the average population size in each village, the
dominant STH species and the intensity of transmis-
sion prior to the start of the trials are all parameters
in the simulations. The time scale of the trials is set
at 5 years with three annual rounds of chemother-
apy. The demography of the villages is set as that of
Kenya from the household survey 2003–2005. Migra-
tion in and out of the trial villages is set at zero in
most of the experiments but how migration influ-
ences outcomes is examined in a separate set of
experiments.
The deterministic model discussed in the previous
section is employed to determine what level of coverage
will lead to crossing the breakpoint in transmission with
3 years of annual treatment for a given STH species and
initial R0 value.
Parameter uncertainty is also examined with respect to
changes in R0, the negative binomial k value and the se-
verity of density dependence on fecundity.
The focus is on the PPV, in terms of the percentage of
villages detected as having eliminated transmission that
in fact truly did eliminate infection. Sampling of each
village population is not addressed, but in practice, as
opposed to within the stochastic simulations where all
infection levels in all people are known, this must be
fully cross-sectional and adherence to treatment must be
followed longitudinally.
Fig. 4 Stochastic simulations. Two stochastic simulations of three annual rounds of chemotherapy to control Ascaris (R0 = 2.2; k = 0.9, L = 1 year, ɣ= 0.07)
(Infants 0% coverage, 90% coverage of Pre-SAC and SAC, 80% coverage of Adults) showing elimination and bounce back. The mean proportion infected
(from 300 replicate runs) are shown for those simulations that result in elimination and those that result in bounce back (parameters as in Table 3)
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Results
Simulation experiments
The simulation experiments are all set to mimic a trial
run over 5 years with a randomized set of villages of
given population sizes with three annual rounds of
MDA (with defined coverage levels in Pre-SAC, SAC
and Adults) and 2 years of monitoring at the end of
which the prevalence of infection in the total village is
recorded (at time t = 5 years). In the replicated experi-
ments, the frequency distributions of the number or
proportion of villages with a prevalence of x (defined as
a proportion infected) is recorded. An illustrative ex-
ample for Ascaris is plotted in Fig. 5. If the trial criterion
for elimination of transmission is a prevalence less than
y at year 5, then the PPV and NPV can both be calcu-
lated from these frequency distributions created by the
stochastic model.
In terms of a randomized cluster trial design, the
villages would be chosen at random to fall into one of
two groups (community wide treatment or Pre-SAC and
SAC treatment only). The villages should be grouped by
both the dominant STH species and the transmission in-
tensity (low, medium or high) environments before
randomization.
The critical issues here are what value should be
assigned to the statistic y and what fraction of villages
should be predicted to fall in the elimination category?
The illustrative example portrayed in Fig. 5 provides a
possible solution. For the first query, namely, the value
of y, it should be a prevalence which does not permit
too much overlap in the two distributions of elimination
and bounce back. In the example shown this value of y
is 0.27, or a prevalence of 27% at year two post-cessation
of treatment. The second issue is the value of the pre-
dicted percentage of trials falling in the elimination cat-
egory. The figure was 88% for the example shown in
Fig. 5. Given the short duration of the community-based
trial suggested (a total of 5 years), this figure should cer-
tainly be above 80% and preferably above 90%. It is to be
hoped that if 5 years of LF treatment has occurred be-
fore the STH trial takes place, a much lower value of the
statistic y could be used (say 5 to 15%) which will in turn
influence the fraction of villages in which transmission
ceases.
The next step is the calculation of the PPV and NPV.
This is best illustrated by a series of examples of param-
eter assignments based on Ascaris infection detailed in a
series of graphs of these distributions for various as-
sumptions on village replicates and average population
size per village.
Figure 6 records the first example, and plots the
distribution of parasite prevalence after 3 annual
rounds of treatment and 2 years after the end of MDA,
for villages in which elimination occurred, and villages
in which bounce back resulted. These simulations were
conducted for 300 villages, each with a population of
500 people. The epidemiological parameter settings
were as defined in Table 3 and derived from an epi-
demiological study in India [35, 38]. The levels of ef-
fective drug coverage for the community-based arm
Fig. 5 Prevalence of Ascaris after MDA. Illustrative example of the prevalence of Ascaris infection in a village at year 5 after three rounds of annual
treatment measured followed by 2 years of no treatment. The graph records the frequency distribution of the proportion of a population of a
village infected in villages in which transmission is eliminated (blue bars) and those in which bounce back occurs (green bars). In Figs. 6, 7, 8 and
9 all probabilities are conditional with the blue bars and green bars each summing to 1
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derived from the deterministic model to achieve elimin-
ation within 3 years were Pre-SAC and SAC = 90%, and
Adults = 80%.
The insert text box in Fig. 6 gives the PPV = 100% and
the NPV = 62% for a prevalence (the value of y) of 30%
at the end of the 2 years of reinfection. The 95% confi-
dence limits (98–100%) are recorded in Table 4 along
with likelihood ratios and the raw data from the simula-
tions summarised as the number of simulated village
populations in which bounce back and transmission
interruption were detected correctly (true) or incorrectly
(false) [40, 41]. The overall percentage of villages in
which transmission was interrupted was 88%, and the
95% confidence limits are again recorded in Table 4. If
the point of observation, after the end of MDA, is de-
creased to 3 months, as opposed to 2 years, the chance
of success in the detection of elimination falls a little as
illustrated in Fig. 7, with PPV and NPV values of 94.4
and 67.7%, respectively, and wider confidence bounds
(Table 5). Figure 7 shows overlapping distributions of
prevalence in the elimination and bounce back villages
at 3 months post-cessation of MDA This is a simple
consequence of some infection continuing over the 3-
month period in the egg-contaminated environment
after transmission has been interrupted which acts to
slightly blur the separation of those villages in which
transmission has been interrupted and those in which
bounce back will occur in the absence of any other
changes in hygiene and sanitation. However, the differ-
ence is small, which may support an earlier assessment
than at 2 years post-cessation of MDA.
At this level of high replication (300 villages of 500
people per village), the chance of detecting elimination
is good, with a very high PPV. If the number of villages
is decreased to 100, each with the same population of
500, the calculated PPV and NPV values are reduced a
little to 98.9 and 70%, respectively, but the percentage of
villages in which elimination occurs is changed little
(92%; confidence limits recorded in Table 6 and Fig. 8).
There is little to be lost from this reduction of village
replication, except in the NPV value detecting bounce
back.
Conversely, decreasing the number of people per vil-
lage to 250, but keeping the number of village replicates
in a cluster the same at 300, reduces the elimination per-
centage to 82%, and decreases the PPV to 97% and in-
creases the NPV to 76% (Figs. 9 and 10 and Table 7).
There is an obvious interplay between population size
Fig. 6 Ascaris prevalence distributions 1. Predicted distribution of Ascaris prevalences after three annual rounds of treatment and 2 years after the end
of MDA for villages in which elimination occurred and villages in which bounce back resulted. The insert text box gives the PPV and NPV for a
prevalence of 30%. These simulations were conducted for 300 villages each with a population of 500 people with MDA coverage of 0% infants - 90%
pre-SAC - 90% SAC - 80% adults. Parameter values as defined in Table 3. The predicted percentage elimination in the replicates is 88%
Table 3 Parameter values for the Ascaris stochastic simulations
of MDA impact (from [33])
Parameter Value
Basic reproductive number, R0 2.12
Density dependent fecundity parameter, ɣ 0.07
Parasite life expectancy in the human host, L 1 year
Negative binomial parameter, k 0.9
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within a village and the number of villages assigned to a
cluster within an arm of the trial in terms of the calcula-
tions of the PPV and NPV values plus associated confi-
dence limits. Reducing population size within a village to
around 250 people may be needed to match the reality
of chosen village sites for the trial. It is encouraging that
it is predicted that the percentage elimination remains at
a high level for this population size (Table 7). In terms
of the number of villages in each cluster, the simulations
suggest 100 is adequate to keep the PPV value high with
reasonable confidence limits (Table 6). In defined set-
tings, logistical and resource constraints will be probably
the greatest influence on the choice in this trade-off.
Once sites are selected, the simulations need to be
conducted to look at the predicted percentage elimin-
ation and concomitantly, the PPV and NPV values for a
series of defined prevalences after a defined period post
the cessation of MDA. This period could be much
shorter than 2 years (the time employed in the calcula-
tions displayed in Figs. 6, 8 and 9 and Tables 4, 6 and 7)
as illustrated in Fig. 7 and Table 5.
Adherence
It has already been mentioned that adherence to treat-
ment at each of the three rounds of treatment is key,
given the high coverage figures needed to break trans-
mission in 3 years predicted by the deterministic model
(80 to 90% of Pre-SAC and SAC and 80% of Adults).
An analysis based on the model of the impact of vari-
ous assumptions on adherence, from random at each
round given a defined coverage level, to persistent non-
adherers, shows that some patterns, in particular, per-
sistent non-adherers at low to moderate levels, can sig-
nificantly prolong the period of annual treatment
required to break transmission beyond 3 years. This
issue is illustrated in Fig. 11. These calculations highlight
the importance of measuring, in a longitudinal observa-
tional programme, individual adherence at each round
of annual treatment.
Migration
As noted earlier (Fig. 1), the adult male population
(and in some cases females as well) in many poor
communities, must migrate to towns or cities to find
employment. These migrant labourers may return to
their home villages at frequent intervals to visit family
and friends. The impact of migration within any trial
of breaking transmission can be examined using the
stochastic model. The predictions of a simple simula-
tion experiment are presented in Figs. 12 and 13. They
are based, on the assumption of migrants being
chosen first at random from the prevailing demo-
graphic age profile (illustrated in Fig. 12) and then as-
cribed a worm burden chosen at random from the
overall population distribution prevailing in the village
they migrated from (also illustrated in Fig. 12). The
simulated outcomes of impact on the percentage elim-
ination in a set of villages which migrants return to
are recorded in Fig. 13 as a function of the number of
migrants who return 3 months after the cessation of
the three rounds of annual MDA. The calculations
show clearly that high migration rates within villages
of around 300 people can greatly reduce the chance of
breaking transmission. The key issue is the measure-
ment of migration rates, village by village, and season
by season (migrating for employment is often sea-
sonal). Treatment could be offered on the return of
migrant labourers to their home village.
In the stochastic simulations portrayed in Figs. 5, 6, 7,
8 and 9, it was assumed that transmission between
Table 4 Confidence limits (95%) for PPV and NPV values for
simulations presented in Fig. 6. Prevalence threshold 30% two
years after cessation of MDA. Data from 300 village simulations
with 500 people per village





Test positive 0 242 242
Test negative 36 22 58







Prevalence of interruption 0.880 0.836 0.913
Sensitivity 0.917 0.875 0.946
Specificity 1 0.880 1
Probability of simulation being
either transmission interruption
or bounce back
Interruption 0.807 0.756 0.848
Bounce back 0.193 0.151 0.243
For predicted elimination -
probability of being true or false
True positive (PPV) 1 0.982 1
False positive 0 0 0.019
For predicted bounce back -
probability of true or false
True negative (NPV) 0.621 0.483 0.741
False negative 0.379 0.258 0.516
Likelihood ratios
Positive (C) Infinity – Infinity
Negative (C) 0.083 0.056 0.124
Positive (W) Infinity – Infinity
Negative (W) 0.611 0.431 0.867
Abbreviations: C conventional, W weighted by prevalence
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villages could be ignored. This is a key assumption, and
needs to be verified by detailed analyses of migration
and movement between villages, and also molecular gen-
etic studies based on whole of partial genome sequen-
cing studies of ‘who infects whom’.
Sensitivity of stochastic predictions to parameter
uncertainty
There are two major sources of parameter uncertainty.
The first concerns individual parameter uncertainty due
to difficulties in measurement. The second concerns
variation in key parameters between the villages in a
given cluster. Hopefully, the latter can be analysed once
the baseline data is collected for each village and due ac-
count taken of such variation in the design of the trial.
The former is more important in the context of this
paper, and our analyses focus on how such variability in-
fluences the two distributions of elimination and bounce
back. Figure 13 records three examples of parameter
variation. The calculations were done by taking one
chain of parameter estimates from a Monte Carlo Mar-
kov Chain (MCMC) calculation in fitting the model to
data recording Ascaris infection intensity by age [33, 36].
Given the definition of R0 (with transmission and
reproduction parameters in the numerator and mortality
terms in the denominator), parameter values are corre-
lated so sets were chosen from one fitting chain as the
system converges to the best fit set.
Figure 14 shows clearly that parameter variation
strongly influences the PPV and NPV values. The value
of the overall transmission intensity is particularly influ-
ential. High values generate more bounce backs with a
fixed level of coverage as to be expected. These results
highlight the importance of parameter estimation at
baseline in trial design.
Discussion
The methodological approach described in this paper
aims to help in the design of a randomized trial to detect
transmission interruption of STH species under repeated
rounds of MDA. Figures 3 and 14 outline what needs to
be done in a series of steps (7 in total) to apply the sto-
chastic randomized trial simulator to help design a
‘transmission interruption’ randomized cluster trial, with
a number of stratifications; namely, which age groups to
be treated (two arms), which is the dominant STH spe-
cies (three possible stratifications) and which intensity of
transmission setting (three possible stratifications). If
LF-related MDA has taken place over the past 5 years
before the start of the trial (a key selection criterion for
DeWorm3 in site selection for the trials), most settings
will have a low initial effective R value, but may be either
low, medium of high R0 in terms of the pristine trans-
mission potential in the chosen settings [28].
There are many uncertainties in some of these trial de-
sign steps, the most important of which is the resources
that will be available to include sufficient villages in each
cluster and over what duration of time the trials are to be
run [29]. Others include average village population size, the
accurate measurement of migration in and out of villages,
the measurement of adherence to treatment, and how
many arms/stratifications to include in the overall trial.
It may be necessary, due to logistical constraints and
the resources available, to reduce the number of
Fig. 7 Ascaris prevalence distributions 2. Identical to Fig. 6 but with the observation period after the end of MDA set at 3 months and the
prevalence threshold set at 30%
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stratifications. An obvious simplification is the treat-
ment of Pre-SAC and SAC only - since this will fail in
most settings. However, one desired output from the
trials is to influence WHO policy, which at present spe-
cifies the treatment of these two groups. If that arm
cannot be discarded, the other stratification options are
to focus on just one STH species such as hookworm.
This parasite is somewhat easier to eliminate than say
Ascaris (because of its typically rapid bounce back time
due to the 1 year average lifespan in the human host)
or Trichuris (two drugs needed to achieve good effi-
cacy) because of its slower dynamic population turn-
over relative to the other two major species. A further
option is to only conduct trials in low R0 transmission
settings (or after many rounds of LF treatment such
that the effective R is low).
Other issues concern the setting of the prevalence
level, 2 years after MDA cessation, at which to
estimate the PPV and NPV values - and what levels
of these two statistics should be aimed for [29]? A
sensible value for prevalence, to insure high PPV
values, will have to be selected for each trial site and
perhaps for each village based on simulation calcula-
tions. The selection criteria should be high PPV and
NPV values and tight 95% confidence limits. This
should allow good discrimination between the prob-
ability distributions for the elimination and bounce
back outcomes. If transmission is very low prior to
the start of the trial this could be set at 5%. Popula-
tion size within villages needs to be sufficient not to
exacerbate chance or stochastic effects. The trial
simulations suggest a lower bound of 250 people per
village is adequate to give high PPV and NPV values‚
if a reasonably high fraction of the villagers are sam-
pled at the end of MDA. Population extinction by
chance alone is more likely in small populations of
hosts‚ hence robust conclusions that can be applied
Table 5 Confidence limits (95%) for PPV and NPV values for
simulations presented in Fig. 7. Prevalence threshold 30.0%
three months after cessation of MDA. Data from 300 village
simulations with 500 people per village







Test positive 15 254 269
Test negative 21 10 31










Sensitivity 0.992 0.929 0.980
Specificity 0.583 0.409 0.740
Probability of simulation being either transmission interruption or
bounce back
Interruption 0.9 0.855 0.930
Bounce back 0.1 0.072 0.145
For predicted elimination - probability of being true or false
True positive (PPV) 0.944 0.908 0.967
False positive 0.055 0.032 0.092
For predicted bounce back - probability of true or false
True negative (NPV) 0.677 0.485 0.826
False negative 0.322 0.173 0.514
Likelihood ratios
Positive (C) 2.309 1.568 3.401
Negative (C) 0.064 0.034 0.124
Positive (W) 16.933 10.347 27.713
Negative (W) 0.476 0.277 0.817
Abbreviations: C conventional, W weighted by prevalence
Table 6 Confidence limits (95%) for PPV and NPV values for
simulations presented in Fig. 8. Prevalence threshold 30.0% two
years after cessation of MDA. Data from 100 village simulations
with 500 people per village







Test positive 1 89 90
Test negative 7 3 10
Totals 8 92 100
95% Confidence limits
Estimated value Lower limit Upper limit
Prevalence of interruption 0.920 0.844 0.962
Sensitivity 0.967 0.901 0.991
Specificity 0.875 0.447 0.993
Probability of simulation being either transmission interruption or
bounce back
Interruption 0.9 0.819 0.948
Bounce back 0.1 0.052 0.180
For predicted elimination - probability of being true or false
True positive (PPV) 0.989 0.930 0.999
False positive 0.011 0.001 0.069
For predicted bounce back - probability of true or false
True negative (NPV) 0.700 0.354 0.919
False negative 0.300 0.081 0.646
Likelihood ratios
Positive (C) 7.739 1.237 48.42
Negative (C) 0.037 0.012 0.117
Positive (W) 89.000 12.673 625.03
Negative (W) 0.428 0.153 1.201
Abbreviations: C conventional, W weighted by prevalence
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broadly should be based on large community sizes in
the range of 200 to 300 people per village. How
many villages to include in a cluster is also an
important issue, which ultimately will be controlled by the
resources available, and logistical and technical issues
within the countries chosen for the trials. However, the
number of villages in each cluster will need to be calcu-
lated, given the need to compare the probability distribu-
tions for the two outcomes and assess the degree of
overlap. There is an obvious trade-off between the magni-
tude of the PPV and NPV values. Which to maximise
in sample calculations will depend on which is the
more important outcome to detect accurately, elimin-
ation or bounce back? In this trial it would seem that
maximising the likelihood of correctly detecting
elimination of transmission is a higher priority. These
issues are discussed in more detail in a companion
paper [29].
Fig. 8 Ascaris prevalence distributions 3. Identical to Fig. 7 but with replication in 100 villages with 500 people per village. The percentage
elimination is 92%
Fig. 9 Ascaris prevalence distributions 4. Identical to Fig. 7 but with replication in 300 villages and 250 people per village. The percentage
elimination is 82.0%
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Perhaps the main challenges lie more with the acquisi-
tion of good quantitative epidemiological data at the base-
line on infection, adherence to drug treatment and
migration. STH epidemiology has not advanced rapidly
over the past few decades in terms of applying modern
statistical tools to parameter estimation and good surveys
practices both horizontal and longitudinal. The small
numbers of estimates of the degree of parasite aggrega-
tion, the presence of predisposition and the basic repro-
ductive number, R0, in the published literature are a
reflection of this past trend. The importance of this relates
to the degree of variation present between villages within
a cluster. This must be measured carefully, as well illus-
trated in the section on parameter uncertainty (Fig. 14).
The variability in a cluster has two sources, true uncer-
tainty in measurement and variation in transmission in-
tensity and other population dynamic parameters between
the villages. Diagnostics will clearly play an important role
in the validity of a chosen epidemiological measure for
transmission interruption. There is a major difference
between Kato Katz and q-PCR measures (see Fig. 2). It is
to be hoped that the conduct of the DeWorm3 trials will
stimulate greater quantitative precision in STH epidemio-
logical study.
The problem with the choice of the PPV/NPV statis-
tics is in their dependency on the chosen prevalence at
a defined time point post cessation of MDA at which to
perform the PPV/NPV calculation. However, confidence
limits and sensitivity and specificity, can be defined for
these two statistics in relation to the chosen prevalence
value. The aim is to keep PPV and NPV values high
with tight 95% confidence bounds. As noted earlier, it
may be best to focus on keeping the PPV value high in
the choice of sample size of people per village and the
number of villages per cluster.
The calculations presented in this paper are aimed
to stimulate discussion on trial design before protocols are
Fig. 10 Effects of immigration. Immigration of infected people between village movements: basic data on demography and parasite distributions
per person (k = 0.65, from [38])
Table 7 Confidence limits (95%) for PPV and NPV values for
simulations presented in Fig. 9. Prevalence threshold 30.0% two
years after cessation of MDA. Data from 300 village simulations
with 250 people per village







Test positive 6 232 238
Test negative 47 15 62









Sensitivity 0.939 0.900 0.964
Specificity 0.887 0.763 0.953
Probability of simulation being either transmission interruption or
bounce back
Interruption 0.792 0.742 0.837
Bounce back 0.207 0.163 0.258
For predicted elimination - probability of being true or false
True positive (PPV) 0.974 0.943 0.990
False positive 0.025 0.010 0.057
For predicted bounce back - probability of true or false
True negative (NPV) 0.758 0.630 0.854
False negative 0.242 0.146 0.5370
Likelihood ratios
Positive (C) 8.300 3.903 17.640
Negative (C) 0.068 0.042 0.112
Positive (W) 38.667 17.544 85.220
Negative (W) 0.319 0.203 0.501
Abbreviations: C conventional, W weighted by prevalence
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set for a series of chosen study sites. They are also
aimed to promote the use of individual-based stochas-
tic models of non-linear parasite transmission, firmly
grounded on parameters estimated from field study
sites, to sharpen trial design for infectious disease
control assessments and hence to reduce the likeli-
hood of errors in design and associated costs. Where
significant non-linearities are present in dynamical
systems, intuition alone is not a good guide to the in-
terpretation of observed pattern. Such non-linear pat-
terns are part of the life-cycles of all helminth
infections of humans.
One of the major publications of the pioneering hel-
minth epidemiologist Nelson Hairston begins with a
quote from L. W. Hackett, taken from the book entitled
‘Malaria in Europe’ published in 1937 [37]. It is well
worth repeating, in light of the complexities introduced
in epidemiological study by the non-linear transmission
dynamics of helminth parasites. “A closer collaboration
between biometricians and parasitologists, and a better
acquaintance ship of each with the methods of the other,
is one of the most useful things we can work for today”.
This sentiment is as applicable in 2016 as it was in 1937
when Hackett’s book was first published.
Fig. 11 Adherence to treatment. The impact of various assumptions on adherence to drug treatment on the deterministic predictions the
number of years of MDA at coverage levels of Pre-SAC and SAC at 90% and Adults at 80% before the breakpoint in transmission is crossed [39]
Fig. 12 Effects of immigration. Immigration of people 3 months post end of 3 years of MDA - from outside the treated village - who are drawn
at random from a worm distribution per person and human age distribution data identical to that pertaining in the village prior to treatment
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Fig. 14 Flow chart summary of the steps (following on from Fig. 3) in the suggested procedures and the calculations required to arrive at the
PPV and NPV values using the stochastic trial simulation model
Fig. 13 Parameter sensitivity. Some simulation experiments showing the sensitivity of the two distributions of elimination and bounce back
2 years after cessation of three annual rounds of chemotherapy to control Ascaris (MDA coverage as 0% infants - 90% pre-SAC - 90% SAC - 80%
adults) with different parameters sets. Note several parameters vary simultaneously since the sets are taken from the Monte Carlo Markov Chain
fitting of the model to age intensity data. Three different set of parameters chosen from one chain of an MCMC run are recorded. A stochastic
model is used to convert epg counts for Ascaris to worm counts with density dependence in egg production built in
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Conclusions
A stochastic individual based model is developed to
mimic the transmission dynamics of soil transmitted hel-
minths (STH) and their control by mass drug adminis-
tration (MDA). The model is employed to mimic cluster
randomized trials of the impact of MDA. The calcula-
tions are designed to consider various trial arms and
stratifications; namely, community-based treatment and
pre-school aged children (Pre-SAC) and school aged
children (SAC) only treatment (the two arms of the
trial), different STH transmission settings of low,
medium and high, and different STH species mixes. The
complications introduced by the choice of statistic to de-
fine success or failure, varying adherence to treatment,
migration and parameter uncertainty are analysed. The
simulations demonstrate the power of the methods in
helping to design cluster randomized trials for infectious
disease agents with non-linear transmission dynamics.
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